[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CA3205010A1 - Antibody variable domains and antibodies having decreased immunogenicity - Google Patents

Antibody variable domains and antibodies having decreased immunogenicity

Info

Publication number
CA3205010A1
CA3205010A1 CA3205010A CA3205010A CA3205010A1 CA 3205010 A1 CA3205010 A1 CA 3205010A1 CA 3205010 A CA3205010 A CA 3205010A CA 3205010 A CA3205010 A CA 3205010A CA 3205010 A1 CA3205010 A1 CA 3205010A1
Authority
CA
Canada
Prior art keywords
seq
sequence
antibody
amino acid
antibody variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3205010A
Other languages
English (en)
French (fr)
Inventor
Maria JOHANSSON
Julia Tietz
Stefan Warmuth
Matthias Brock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numab Therapeutics AG
Original Assignee
Numab Therapeutics AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP20216957.9A external-priority patent/EP4019547A1/en
Priority claimed from PCT/EP2021/064427 external-priority patent/WO2021239987A1/en
Application filed by Numab Therapeutics AG filed Critical Numab Therapeutics AG
Priority claimed from PCT/EP2021/087618 external-priority patent/WO2022136693A1/en
Publication of CA3205010A1 publication Critical patent/CA3205010A1/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35Valency
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567Framework region [FR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3205010A 2020-12-23 2021-12-23 Antibody variable domains and antibodies having decreased immunogenicity Pending CA3205010A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP20216957.9A EP4019547A1 (en) 2020-12-23 2020-12-23 Multispecific antibodies having specificity for il-4r and il-31
EP20216957.9 2020-12-23
EP21154786 2021-02-02
EP21154786.4 2021-02-02
PCT/EP2021/064427 WO2021239987A1 (en) 2020-05-29 2021-05-28 Multispecific antibody
EPPCT/EP2021/064427 2021-05-28
PCT/EP2021/087618 WO2022136693A1 (en) 2020-12-23 2021-12-23 Antibody variable domains and antibodies having decreased immunogenicity

Publications (1)

Publication Number Publication Date
CA3205010A1 true CA3205010A1 (en) 2022-06-30

Family

ID=86769674

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3205010A Pending CA3205010A1 (en) 2020-12-23 2021-12-23 Antibody variable domains and antibodies having decreased immunogenicity

Country Status (7)

Country Link
US (1) US20240084039A1 (ja)
EP (1) EP4267622A1 (ja)
JP (1) JP2024501810A (ja)
KR (1) KR20230125239A (ja)
AU (1) AU2021405066A1 (ja)
CA (1) CA3205010A1 (ja)
IL (1) IL303171A (ja)

Also Published As

Publication number Publication date
JP2024501810A (ja) 2024-01-16
AU2021405066A9 (en) 2024-10-31
KR20230125239A (ko) 2023-08-29
EP4267622A1 (en) 2023-11-01
US20240084039A1 (en) 2024-03-14
IL303171A (en) 2023-07-01
AU2021405066A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
Chiu et al. Antibody structure and function: the basis for engineering therapeutics
JP7442443B2 (ja) 多重特異性抗体
US11261254B1 (en) Antibodies
JP2023501146A (ja) 多重特異性抗体
CA3205036A1 (en) Multispecific antibodies having specificity for il-4r and il-31
EP3915580A1 (en) Multispecific antibody
US20230303694A1 (en) Antibodies that bind gamma-delta t cell receptors
CA3208781A1 (en) Multispecific antibodies having specificity for ror1 and cd3
US20230114801A1 (en) MINIATURE GUIDANCE AND NAVIGATION CONTROL (miniGNC) ANTIBODY-LIKE PROTEINS AND METHODS OF MAKING AND USING THEREOF
CA3183389A1 (en) Bispecific antibody and use thereof
US20240084039A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
US20230203162A1 (en) Multispecific antibody
EP4273162A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
WO2022136693A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
EP4136122A1 (en) Antibody constructs binding 4-1bb and folate receptor alpha and uses thereof
WO2023214047A1 (en) Antibody variable domains and antibodies having decreased immunogenicity
CN116783218A (zh) 具有降低的免疫原性的抗体可变结构域和抗体
EP4292609A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors
AU2023293720A1 (en) Compositions comprising antibodies that bind gamma-delta t cell receptors